Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the development of RedHill’s RHB 104, a combination antibiotic therapy which includes clarithromycin, clofazimine and rifabutin; the removal of the pregnancy contraindication from the European label of Copaxone (glatiramer acetate; Teva) injection 20mg/ml; as well as opinions on the development and potential future use of generic glatiramer acetate.
*Latest* Update 1: February 2017
Original Publication: Nov 2016
*Purchase of this report includes all updates*
Big changes ahead as Ocrevus nears approval. How will it affect your brand?
Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the pending approval of Roche/Biogen’s Ocrevus, a powerful monoclonal antibody for relapsing and progressive MS patients that promises to upend the treatment algorithm.
Get the details in KOL Insight: Multiple Sclerosis.
Based on interviews with 12 US and European KOLs, the report gives you their candid thoughts about 12 marketed therapies and 11 more in the pipeline.
You’ll learn what the future holds for interferons, how oral agents are faring, and how pipeline treatments—from sphingosine modulators, to monoclonal antibodies, pharmaceutical-grade biotin, and other novel mechanisms of action—are likely to compete with established therapies.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“Ocrevus has the potential to really change the landscape and, from a patient perspective, sounds pretty easy.”
EU Key Opinion Leader
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved